Frederiksberg C, Denmark

Klaus Snej Jensen

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.3

ph-index = 1


Company Filing History:


Years Active: 1999-2010

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Klaus Snej Jensen: Innovator in Pharmaceutical Chemistry

Introduction

Klaus Snej Jensen is a notable inventor based in Frederiksberg C, Denmark. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 3 patents. His work primarily focuses on novel compounds that have therapeutic applications.

Latest Patents

One of his latest patents involves the invention of 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts. This invention relates to novel (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts, such as L-tartrate monohydrates and anhydrates. These salts are useful as monoamine neurotransmitter re-uptake inhibitors and are intended for therapeutic use in pharmaceutical compositions. Another significant patent is for crystalline (−)-3R,4R-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}chromane, hydrogen maleate. This invention is aimed at reducing or preventing bone loss and includes a process for preparing the compound.

Career Highlights

Klaus has worked with prominent companies in the pharmaceutical industry, including Novo Nordisk A/S and Neurosearch A/S. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Throughout his career, Klaus has collaborated with notable professionals such as Svend Treppendahl and Scott E McGraw. These collaborations have further enhanced his research and development efforts in the field.

Conclusion

Klaus Snej Jensen is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable innovations. His patents reflect his commitment to advancing therapeutic options for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…